Spain vs Sri Lanka: Statin use vs. average non-HDL cholesterol levels
Spain
3.3
in 2018
Sri Lanka
3.3
in 2018
Spain rank
95th
Sri Lanka rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Spain
- Sri Lanka
How they compare
Spain currently reports 3.3 against 3.3 in Sri Lanka, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Spain ahead.
Spain ranks 95th and Sri Lanka ranks 95th of 191 countries.
Spain has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Spain | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.18 | 2.8 | 1.38 | Spain |
| 1990s | 3.92 | 2.95 | 0.97 | Spain |
| 2000s | 3.68 | 3.13 | 0.55 | Spain |
| 2010s | 3.41 | 3.28 | 0.1333 | Spain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Spain or Sri Lanka?
- Spain, at 3.3 against 3.3 in Sri Lanka as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Spain and Sri Lanka?
- 0, with Spain ahead.
- How many years of comparable data are there for Spain and Sri Lanka?
- 39 years are reported by both, from 1980 to 2018.
- How do Spain and Sri Lanka rank globally for statin use vs. average non-hdl cholesterol levels?
- Spain ranks 95th and Sri Lanka ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.